Chromenopyrimidine derivatives as phosphatidylinsitol phosphate kinase inhibitors

A compound of Formula (I):

• or a pharmaceutically acceptable salt, prodrug, solvate, hydrate, isomer, or tautomer thereof,
• wherein:
• Ring A1 is 6-membered heteroaryl;
• Ring A2 is a monocyclic heteroaryl optionally substituted with one or more R8;
• W is —O—;
• G is —NH—;
• R1 is —N(R5)C(O)R6 or heteroaryl, wherein the heteroaryl is optionally substituted with one or more R7;
• R2 is H;
• R3 and R4 are each independently C1-6 alkyl;
• R5 and R6 when taken together with the atom to which they are each attached form a heterocycle or spiroheterocyclyl, wherein the heterocycle or spiroheterocyclyl is optionally substituted with one or more R7;
• R7 is independently H or C1-6 alkyl;
• R8 is independently —N(R9)C(O)R10, —N(R9)(R10), —OR10, —R10;
• or
• two R8 with the atoms to which they are attached form a heterocyclyl, substituted with one or more R12;
• each R9 or R10 is independently, at each occurrence, C1-6 alkyl or heterocyclyl, wherein the alkyl or heterocyclyl is optionally substituted with one or more R13;
• each R12 is independently C1-6 alkyl, —C(O)R20, —C(O)OR20, or —C(O)N(R20)(R20), wherein the alkyl is substituted with heterocyclyl or —N(R20)(R20);
• R13 is C1-6 alkyl, —N(R20)(R20), or heterocyclyl, wherein the alkyl or heterocyclyl is optionally substituted with one or more R15;
• R15 is C1-6 alkyl, —OH, or halogen;
• R20 is H, C1-6 alkyl, or C3-8 cycloalkyl, wherein the alkyl, or cycloalkyl is optionally substituted with one or more —N(C1-6 alkyl)2, C1-6 alkyl, heterocyclyl, -heterocyclyl-R23, —OC(O)R23, or —S(O)2R23;
• and
• R23 is C1-6 alkyl,
• provided that when two R8 with the atoms to which they are attached form a heterocyclyl substituted with methyl, R1 is not 2-pyrrolidinonyl.